These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 24226526)

  • 1. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.
    Henske EP; Rasooly R; Siroky B; Bissler J
    Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
    Budde K; Gaedeke J
    Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
    Brakemeier S; Bachmann F; Budde K
    Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition.
    Kronick J; Gabril MY; House AA
    Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
    Lam HC; Siroky BJ; Henske EP
    Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
    Coombs EJ
    J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
    Siroky BJ; Yin H; Babcock JT; Lu L; Hellmann AR; Dixon BP; Quilliam LA; Bissler JJ
    Am J Physiol Renal Physiol; 2012 Sep; 303(6):F831-44. PubMed ID: 22791333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
    Boggarapu S; Roberds SL; Nakagawa J; Beresford E
    Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular insights into tuberous sclerosis complex renal disease.
    Siroky BJ; Yin H; Bissler JJ
    Pediatr Nephrol; 2011 Jun; 26(6):839-52. PubMed ID: 21152937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
    Samuels JA
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
    Yu J; Parkhitko AA; Henske EP
    Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
    Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
    Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reprint of: lessons from histopathologic examination of nephrectomy specimens in patients with tuberous sclerosis complex: cysts, angiomyolipomas & renal cell carcinoma.
    Gupta S; Stanton ML; Reynolds JP; Whaley RD; Herrera-Hernandez L; Jimenez RE; Cheville JC
    Hum Pathol; 2023 Mar; 133():136-152. PubMed ID: 36894367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.
    Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA
    Nephron; 2016; 134(2):51-58. PubMed ID: 27504842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
    N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible prevention of tuberous sclerosis complex lesions.
    Kotulska K; Borkowska J; Jozwiak S
    Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons from histopathologic examination of nephrectomy specimens in patients with tuberous sclerosis complex: cysts, angiomyolipomas, and renal cell carcinoma.
    Gupta S; Stanton ML; Reynolds JP; Whaley RD; Herrera-Hernandez L; Jimenez RE; Cheville JC
    Hum Pathol; 2022 Nov; 129():123-139. PubMed ID: 36115585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.
    Henske EP
    Pediatr Nephrol; 2005 Jul; 20(7):854-7. PubMed ID: 15856327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.